Evaluating Palonosetron Hydrochloride Capsules for Preventing Nausea and Vomiting from Chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and effectiveness of Palonosetron hydrochloride capsules in preventing acute nausea and vomiting caused by moderate emetic chemotherapy. It focuses on patients with malignant tumors undergoing chemotherapy and analyzes the clinical benefits and characteristics of the population receiving this oral medication. The study will compare the oral administration of this antiemetic to traditional intravenous methods, emphasizing the convenience of oral therapy for both clinicians and patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines);
* 18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months;
* Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes were basically normal;
* All patients signed the informed consent form

Exclusion Criteria:

* Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant women and lactating women;
* People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs;
* Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have brain metastasis, intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.

Where it's running

• The First Affiliated Hospital, the Air Force Medical University
  Xi'an, Shaan'xi, China Recruiting

Study contacts

• Study coordinator: Liu Hong, master
• Email: hongliu1@fmmu.edu.cn
• Phone: 13709284513

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sedation with dexmedetomidine, propofol, or both during cataract surgery

  This project will test whether dexmedetomidine, propofol, or their combination (each given with fentanyl) provides the best sedation, safety, and surgeon satisfaction for adults having cataract surgery.

  Recruiting Saint-Joseph University · Beirut · NCT07556133

• Tradipitant for GLP-1R agonist–related nausea and vomiting in adults with overweight or class I–II obesity

  This trial will test if tradipitant can reduce nausea and vomiting caused by GLP-1 receptor agonist weight-loss medicines in adults who are overweight or have class I–II obesity.

  Recruiting at 3 sites Phase 3 Vanda Pharmaceuticals · Los Angeles, California and 9 other locations · NCT07446439

• Using Fosaprepitant to Treat Nausea and Vomiting

  This study is testing if a new medication called fosaprepitant can help people with nausea and vomiting feel better compared to the usual treatment they receive.

  Recruiting Phase 2/3 Montefiore Medical Center · The Bronx, New York · NCT06382012

• Combining electroacupuncture with antiemetic therapy for nausea in breast cancer patients

  This study is testing if combining electroacupuncture with standard anti-nausea medication can help breast cancer patients feel less sick during chemotherapy.

  Recruiting Phase 3 Lanzhou University Second Hospital · Lanzhou, Gansu · NCT06314906

• Using electroacupuncture to prevent nausea and vomiting in breast cancer patients undergoing chemotherapy

  This study is testing if adding electroacupuncture to regular anti-nausea medications can help breast cancer patients undergoing chemotherapy avoid nausea and vomiting.

  Recruiting Phase 3 Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT06200168

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.